Phillip M. Pierorazio, MD, presented “Recent Findings on Upper Tract Urothelial Carcinoma Presented at the AUA’s 2019 Annual Meeting” for the Grand Rounds in Urology audience in August, 2019.

How to cite: Pierorazio, Phillip M. Recent Findings on Upper Tract Urothelial Carcinoma Presented at the AUA’s 2019 Annual Meeting” August, 2019. Accessed Jul 2024.​/

Recent Findings on Upper Tract Urothelial Carcinoma Presented at the AUA’s 2019 Annual Meeting – Summary:

Phillip M. Pierorazio, MD, reviews data from one presentation and two moderated posters at the American Urological Association’s 2019 Annual Meeting related to upper tract urothelial cancer (UTUC). He discusses the promising efficacy of UGN-101 to treat low-grade UTUC as shown in the OLYMPUS trial, details data that supports the use of intravesical therapy to prevent recurrence of bladder cancer in patients with upper-tract disease, and argues that concordant or discordant pathology should have little bearing on treatment options for patients suspected of having high-grade UTUC.

For more information on upper-tract urothelial carcinoma, please visit our next-generation learning center.


Dr. Phillip Pierorazio is an Associate Professor of Urology and Oncology in the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland. Dr. Pierorazio is originally from New York. He received his undergraduate degree from Georgetown University in Washington, DC, and his medical degree from Columbia University Vagelos College of Physicians & Surgeons in New York City, where he also completed a Doris Duke Clinical Research Fellowship in Urologic Oncology.

Dr. Pierorazio has expertise in all malignancies of the urinary tract and performs both open and minimally-invasive surgeries, including laparoscopic and robotic surgeries of the kidney, bladder, and prostate, as well as retroperitoneal lymph node dissection for testicular cancer. He has a special interest in kidney cancer, including partial nephrectomy for early stage disease and high-risk surgeries for patients with advanced cancers.

His research interests parallel his clinical practice, including high-risk prostate and urothelial cancer. He has a special interest in testicular and kidney cancer (renal cell carcinoma), studying both advanced and early-stage disease.

Dr. Pierorazio runs the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry—one of the largest active surveillance registries for patients with small kidney tumors. He sits on both the AUA and the National Comprehensive Cancer Network (NCCN) Guidelines Committees for Kidney Cancer.

He is also the Director of the Division of Testicular Cancer and a member of the NCCN Guidelines Committee. He also works with a number of testicular cancer advocacy groups around the country. He runs the testicular cancer “Go-Team” and coordinates the department’s research efforts in testicular cancer.

Dr. Pierorazio is the recipient of a number of academic awards, including the American Urologic Association Essay Contest and the NCCN Young Investigator Award, and has presented his research at a number of national and international meetings. He has written and published numerous research articles, textbook chapters, and video presentations in the field of urologic oncology.